Skip to content

ICH E8 (R1) General Considerations for Clinical Studies Impact on Data Management

Date: April 5, 2022

The ACDM Regulatory Considerations have reviewed the Revision 1 to the ICH E8 Guidelines and have provided an overview here.

 


 

Explore More News

Welcome CROss Alliance as a corporate member

The Association for Clinical Data Management (ACDM) is delighted to welcome CROss Alliance . . .

Read More

Regulatory Considerations DMEG Update

With mixed feelings, we share that Silvia Pérez Torres, current chair of the ACDM . . .

Read More

Newsletter Committee’s Christmas Copilot Tips

In a time when we are constantly surrounded by artificial intelligence and feel the need . . .

Read More

Welcome Data Magik as a corporate member

The Association for Clinical Data Management (ACDM) is delighted to welcome Data Magik as . . .

Read More

Welcome The Institute of Cancer Research – Scientific Computing as a corporate member

The Association for Clinical Data Management (ACDM) is delighted to welcome The Institute . . .

Read More

Newsletter Committee: Meet Federica

The ACDM is delighted to welcome Federica Migliore of IQVIA to the Newsletter . . .

Read More

Welcome P95 as a corporate member

The ACDM: Association for Clinical Data Management is delighted to welcome P95 as a new . . .

Read More

AI Symposium Session Summary: Is AI in clinical trials delivering measurable ROI?

At the 4th Annual ACDM Symposium on Artificial Intelligence (AI) in Clinical Trials, the . . .

Read More

Newsletter Committee: Meet Neha

The ACDM is delighted to welcome Neha Shah of ITM to the Newsletter Committee. Neha shares . . .

Read More

Newsletter Committee: Meet Sylvain

The ACDM is delighted to welcome Sylvain Berthelot of CRScube to the Newsletter . . .

Read More

Welcome VHypotenuse as a corporate member

The ACDM: Association for Clinical Data Management is delighted to welcome VHypotenuse as . . .

Read More

Newsletter Committee: Meet Marta

The ACDM is delighted to welcome Marta Kowalska of CluePoints to the Newsletter . . .

Read More